Sponsor Pipeline

Orion Corporation, Orion Pharma Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
2
Recruiting
5
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-15 NCT03436485
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant…		 date change Primary completion pushed: 2026-07-31 -> 2026-10-31
2026-08-15 NCT03436485
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant…		 date change Completion pushed: 2026-07-31 -> 2026-10-31
Active Trials by Phase
Phase 1/2
3
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT07563738 A 2-part Phase 1/2 Open-label Trial on ODM-212 Mesothelioma Recruiting
NCT06725758 A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid… Solid Tumours Recruiting
NCT03436485 Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant… Prostate Cancer Metastatic Active, Not Recruiting
Disease Areas
Prostate Cancer (1) Non-Small Cell Lung Cancer (NSCLC) (1) Lung Cancer (1) Pancreatic Cancer (1) Mesothelioma (1)
Get alerts when Orion Corporation, Orion Pharma's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free